ARID1A and neoplasm: The involvement of ARID1A in maintaining genomic stability makes cancers with ARID1A mutations potential candidates for therapeutic approaches based on synthetic lethality: an ARID1A− deficient tumor, with its intrinsic genomic instability, may be vulnerable to therapies targeting molecular pathways involving genome maintenance.